Blood test could predict leukemia survival
NCT ID NCT04641910
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether measuring two substances in the blood—FLT3L and IL-6—during chemotherapy can help predict survival in people with acute myeloid leukemia (AML). Researchers will track 201 newly diagnosed AML patients across 25 French hospitals. The goal is to confirm that these blood markers can separate patients into good, intermediate, and high-risk groups, which could guide future treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could give doctors a better tool to predict which AML patients need more or less aggressive treatment.
- What could go wrong
- This is an observational validation study, not a treatment trial. It may confirm the approach works only in this specific group and not in others.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AP-HP Cochin Hospital
Paris, 75014, France
-
Angers University Hospital
Angers, Maine-et-Loire, 49000, France
-
Basque coast hospital center
Bayonne, Pyrénées-Atlantiques, 64102, France
-
Besançon University Hospital
Besançon, Doubs, 25000, France
-
Bordeaux University Hospital
Bordeaux, Gironde, 33076, France
-
Brest University Hospital
Brest, Finistère, 29200, France
-
Béziers Hospital Center
Béziers, Hérault, 34500, France
-
Clermont-Ferrand University Hospital
Clermont-Ferrand, Puy-de-Dôme, 63000, France
-
Grenoble University Hospital
Grenoble, Isère, 38000, France
-
Lyon University Hospital
Lyon, Rhône, 69000, France
-
Mercy Regional Hospital
Metz, Moselle, 57000, France
-
Montpellier University Hospital
Montpellier, Hérault, 34295, France
-
Mulhouse Hospital Center
Mulhouse, Haut-Rhin, 68100, France
-
Nancy University Hospital
Nancy, Meurthe-et-Moselle, 54000, France
-
Nantes University Hospital
Nantes, Loire-Atlantique, 44093, France
-
Nîmes University Hospital
Nîmes, Gard, 30000, France
-
Paoli-Calmette Institute
Marseille, Bouches-du-Rhône, 13000, France
-
Poitiers University Hospital
Poitiers, 86000, France
-
Reims University Hospital
Reims, Marne, 51100, France
-
Rennes University Hospital
Rennes, Ille-et-Vilaine, 35033, France
-
Saint-Etienne University Hospital
Saint-Étienne-de-Montluc, Pays de la Loire Region, 42000, France
-
Saint-Jean Hospital Center
Perpignan, Pyrénées-Orientales, 66000, France
-
Strasbourg University Hospital
Strasbourg, Bas-Rhin, 67200, France
-
Toulouse University Cancer Institute
Toulouse, Haute-Garonne, 31000, France
-
Tours University Hospital
Tours, Indre-et-Loire, 37000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?